Maternal and perinatal outcomes of pre-referral magnesium sulfate treatment in severe preeclampsia patients
Downloads
HIGHLIGHTS
1. Consumption of magnesium sulfate is recommended for prevention against eclampsia.
2. Magnesium sulfate administration to preeclamptic mothers is effective in reducing the risk of eclampsia.
3. Pre-referral magnesium sulfate administration and maternal and perinatal outcomes in severe preeclampsia patients was analyzed.
4. Magnesium sulfate did reduce eclampsia risk, but not ICU and NICU care rates, maternal mortality, perinatal asphyxia, and perinatal mortality.
ABSTRACT
Objectives: This study analyzed the association between pre- referral magnesium sulfate administration and maternal and perinatal outcomes in severe preeclampsia patients.
Materials and Methods: This was a retrospective observational analytic study using cross-sectional design. Samples were 132 pregnant women with preeclampsia referred to dr. Saiful Anwar, Hospital Malang, Indonesia in 2019. Data were taken from the patients' medical records. Maternal outcomes measured in this study were the incidence of eclampsia, ICU care, and maternal mortality, while the perinatal outcomes included the incidence of asphyxia, NICU care, and perinatal mortality.
Results: Patients' history of magnesium sulphate administration significantly associated with the incidence of eclampsia with p-value 0.035 and odds ratio (OR) 2.413, thus consumption of magnesium sulphate could reduce the risk of seizures. However, it did not associate with either maternal ICU care outcomes (p-value 0.087, OR 2.028), or maternal mortality (p-value 0.573). No relationship was found neither between history of magnesium sulphate administration in pregnant women with severe preeclampsia and perinatal outcomes nor with the incidence of asphyxia (p-value 0. 577, OR 0.795), with NICU treatment (p-value 0.205, OR 0.579), and with perinatal mortality (p-value 0.153, OR 3.259).
Conclusion: Magnesium sulfate reduced the risk of eclampsia, yet it did not affect either the rate of ICU care, maternal mortality, incidence rate of perinatal asphyxia, the rate of NICU care, or perinatal mortality.
Say L, Chou D, Gemmill A, et al. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health. 2014;2(6):e323-33. doi: 10.1016/ S2214-109X(14)70227-X. Epub 2014 May 5. PMID: 25103301.
Ministry of Health, Republic of Indonesia. Data dan informasi profil kesehatan Indonesia 2019 [Data and information on health profile Indonesia 2019]. 2019.
Duley L. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: A randomised placebo-controlled trial. Lancet. 2002;359(9321):1877–90. doi: 10. 1016/S0140-6736(02)08778-0
ACOG, Gestational hypertension and preeclampsia, Obstetrics & Gynecology. 2020;135(6):e237-e260 doi: 10.1097/AOG.0000000000003891.
Mawarti Y, Utarini A, Hakimi M. Maternal care quality in near miss and maternal mortality in an academic public tertiary hospital in Yogyakarta, Indonesia: a retrospective cohort study. BMC Pregnancy Childbirth. 2017;17(1):149. doi: 10. 1186/s12884-017-1326-4. PMID: 28532393; PMCID: PMC5440944.
Jaatinen N, Ekholm E. Eclampsia in Finland; 2006 to 2010. Acta Obstet Gynecol Scand. 2016;95(7): 787–92. doi: 10.1111/aogs.12882
RCOG. Magnesium sulphate to prevent cerebral palsy following preterm birth. RCOG Sci Impact Pap. 2011;(29).
Jordan S. Farmakologi kebidanan [Midwifery Pharmacology]. Hartono A, translator. Ester M, editor. Jakarta: EGC 2003.
Yelamali BC, Panigatti P, Pol R, et al. Outcome of newborn with birth asphyxia in tertiary care hospital - a retrospective study. Medica Innovatica. 2014;3(2):59–64.
Shepherd E, Salam RA, Manhas D, et al. Antenatal magnesium sulphate and adverse neonatal out-comes: A systematic review and meta-analysis. PLoS Med. 2019;16(12):e1002988. doi: 10.1371/ journal.pmed.1002988. PMID: 31809499; PMCID: PMC6897495.
Ministry of Health, Republic of Indonesia. Buku saku pelayanan kesehatan ibu di fasilitas kesehatan dasar dan rujukan. Pedoman bagi tenaga kesehatan [Pocketbook on maternal healthcare in first and referral health facilities. Guidelines for healthcare workers]. 1st ed. Moegni EM, Ocviyanti D, editors. 2013.
Gordon R, Magee LA, Payne B, et al. Magnesium sulphate for the management of preeclampsia and eclampsia in low and middle income countries: a systematic review of tested dosing regimens. J Obstet Gynaecol Can. 2014;36(2):154-163. doi: 10.1016/S1701-2163(15)30662-9. PMID: 24518915.
Pardomuan DY, Prasetyo B, Pranadyan R. Pre-referral management of patients with severe pre-eclampsia and eclampsia in a district hospital, Southeast Sulawesi, Indonesia. Maj Obstet Ginekol. 2020;28(3):104. doi: 10.20473/mog.V28I32020. 104-108
Pribadi A. Preeklampsia "Stoppable.” Jakarta: Sagung Seto; 2019.
Chiarello DI, Marín R, Proverbio F, et al. Mechanisms of the effect of magnesium salts in preeclampsia. Placenta. 2018;69:134-139. doi: 10.1016/j.placenta.2018.04.011. Epub 2018 Apr 24. PMID: 29716747.
Duley L, Gülmezoglu AM, Henderson-Smart DJ, Chou D. Magnesium sulphate and other anti-convulsants for women with pre-eclampsia. Cochrane Database Syst Rev. 2010;2010(11): CD000025. doi: 10.1002/14651858.CD000025. pub2. PMID: 21069663; PMCID: PMC7061250.
MacDonald EJ, Lepine S, Pledger M, et al. Pre-eclampsia causing severe maternal morbidity - A national retrospective review of preventability and opportunities for improved care. Aust N Z J Obstet Gynaecol. 2019;59(6):825-830. doi: 10.1111/ajo. 12971. Epub 2019 Mar 18. PMID: 30883684.
Aryana M, Manuaba I. Pendidikan dokter berkelanjutan obstetri dan ginekologi [Continuing medical education on obstetrics and gynecology]. In: PKB Obstetri dan Ginekologi Ke-7. 2015. p. 129–44.
Alexander JM, Gary Cunningham F. Clinical management [Internet]. Fourth Edition. Chesley's Hypertensive Disorders in Pregnancy, Fourth Edition. Elsevier Inc.; 2014. 439–464 p. Available from: http://dx.doi.org/10.1016/B978-0-12-407866-6.00020-1
Hallak M, Cotton DB. Transfer of maternally administered magnesium sulfate into the fetal compartment of the rat: Assessment of amniotic fluid, blood, and brain concentrations. Am J Obstet Gynecol [Internet]. 1993;169(2 PART 1):427–31. Available from: http://dx.doi.org/10.1016/0002-9378(93)90101-N
Wijayanti, Ernawati. Luaran maternal dan neonatal pada preeklampsia berat perawatan konservatif di RSUD Dr. Soetomo Surabaya [Maternal and neonatal outcomes in severe preeclampsia patient with conservative treatment at Dr. Soetomo Surabaya Hospital]. Indones J Obstet Gynecol Sci. 2019;2(2):128–36. doi: 10.24198/obgynia.v2n2.143
Anggraini A, Sumadiono S, Wandita S. Faktor risiko kematian neonatus dengan penyakit membran hialin [Mortality risk factors among neonates with hyaline membrane disease]. Sari Pediatr. 2016;15(2):75. doi: 10.14238/sp15.2.2013.75-80
Quinn CE, Sivasubramaniam P, Blevins M, et al. Risk factors for neonatal intensive care unit admission in Amman, Jordan. East Mediterr Health J. 2016;22(3):163-74. doi: 10.26719/2016.22.3.163. PMID: 27334073.
Copyright (c) 2022 Majalah Obstetri & Ginekologi
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
1. Copyright of the article is transferred to the journal, by the knowledge of the author, whilst the moral right of the publication belongs to the author.
2. The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution-Non Commercial-Share alike (CC BY-NC-SA), (https://creativecommons.org/licenses/by-nc-sa/4.0/)
3. The articles published in the journal are open access and can be used for non-commercial purposes. Other than the aims mentioned above, the editorial board is not responsible for copyright violation
The manuscript authentic and copyright statement submission can be downloaded ON THIS FORM.
